Quintiles and Biogen Idec Announce 5-Year Clinical Development Agreement - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Quintiles and Biogen Idec Announce 5-Year Clinical Development Agreement

Source: Applied Clinical Trials

Quintiles and Biogen Idec have entered a five-year collaboration that is intended to increase clinical trial efficiency, transparency, quality, innovation and operational excellence. Under the agreement, a dedicated team from Quintiles will work with Biogen Idec on the design, planning and execution of Biogen Idec’s Phase II-IV studies and select phase I studies. In addition, Biogen Idec will leverage Quintiles’ technology and systems across its growing portfolio.

Read the full release.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here